Quick Search:       Advanced Search
Impact of immune checkpoint glycosylation in the tumor microenvironment on immunotherapy strategy
Received:July 23, 2022  Revised:December 12, 2022  Click here to download the full text
Citation of this paper:ZHOU Shizhao,CHANG Wenju.Impact of immune checkpoint glycosylation in the tumor microenvironment on immunotherapy strategy[J].Chinese Journal of Clinical Medicine,2024,31(1):126-132
Hits: 356
Download times: 118
Author NameAffiliationE-mail
ZHOU Shizhao Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China  
CHANG Wenju Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China chang.wenju@zs-hospital.sh.cn 
Abstract:Glycosylation is a ubiquitous and crucial post-translational protein modification, and tumor tissues have significantly aberrant protein glycosylation alterations as compared to normal tissues. Immune checkpoints are frequently glycosylated in the tumor microenvironment, and their glycosylated forms play a role in protein stabilization and regulation of protein functions. Immunological checkpoint molecules with numerous N-glycosylation sites, such as programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1), contain glycosylation alterations that impede proteasome breakdown, reduce anti-tumor immunity, and increase immune escape of tumor cells. This paper reviews the effects of glycosylation modification on the expression and function of immune checkpoint molecules in the tumor immune microenvironment, and we anticipate that a new glycosylation intervention strategy will improve the efficacy of tumor immune checkpoint blockade therapy.
keywords:tumor microenvironment  glycosylation modification  immune checkpoint  immunotherapy
HTML  View Full Text  View/Add Comment  Download reader